Why the study?
Does CYP2C19 genotype-directed antiplatelet therapy improve outcomes in patients with acute coronary syndromes receiving clopidogrel?
Does CYP2C19 genotype-directed antiplatelet therapy improve outcomes in patients with acute coronary syndromes receiving clopidogrel?
This CPIC guideline provides evidence-based recommendations for CYP2C19 genotype-directed antiplatelet therapy in patients with ACS undergoing PCI.
May warrant CYP2C19 testing consideration in ACS on clopidogrel; leaves open whether genotype-directed therapy improves outcomes.
CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet prodrug clopidogrel. A common loss-of-function allele, CYP2C19*2 (c.681G>A; rs4244285), is associated with increased risk for serious adverse cardiovascular events in both heterozygous and homozygous patients (~25–50% of the population) with acute coronary syndromes (ACSs) who are receiving clopidogrel, particularly among those undergoing percutaneous coronary intervention (PCI). We provide evidence from published literature and guidelines for CYPC19 genotype–directed antiplatelet therapy (periodically updated at http://www.pharmgkb.org). Clinical Pharmacology & Therapeutics (2011) 90 2, 328–332. doi:10.1038/clpt.2011.132
No takes yet. Share an insight, caveat, or question.
Scott et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: